# CAPItello-291 (NCT04305496)

> Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04305496
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: AstraZeneca
- Conditions: Locally Advanced (Inoperable) or Metastatic Breast Cancer
- Interventions: Fulvestrant; Capivasertib; Placebo
- Enrollment: 818
- Primary outcome: Progression Free Survival: Overall Population (Months) in the Global Cohort
- Primary outcome: Progression Free Survival: Overall Population (Percentage) in the Global Cohort
- Primary outcome: Progression Free Survival: Altered Population (Months) in the Global Cohort
- Primary outcome: Progression Free Survival: Altered Population (Percentage) in the Global Cohort
- Primary outcome: Progression Free Survival: Overall Population (Months) in the China Cohort
- Primary outcome: Progression Free Survival: Overall Population (Percentage) in the China Cohort
- Primary outcome: Progression Free Survival: Altered Population (Months) in the China Cohort
- Primary outcome: Progression Free Survival: Altered Population (Percentage) in the China Cohort

## Commentary we found

- YouTube: 105
- Podcasts: 83
- X threads: 61

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=capitello-291-nct04305496

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04305496", "email": "<work email>"}; the inbox owner confirms by the emailed link.